Article in Human genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 4 institutions in 1 country.
Samantha A StreicherDepartment of Chronic Disease Epidemiology, Yale School of Public Health, 60 College Street, New Haven, CT, 06520-8034, USA.ORCID http://orcid.org/0000-0001-8257-3096
Alison P KleinDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 401 North Broadway, Baltimore, MD, 21287, USA.
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY, 10017, USA.
Robert C KurtzDepartment of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Laufey T AmundadottirLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health,, 9000 Rockville Pike, Bethesda, MD, 20892, USA.
Andrew T DeWanDepartment of Chronic Disease Epidemiology, Yale School of Public Health, 60 College Street, New Haven, CT, 06520-8034, USA.
Hongyu ZhaoDepartment of Biostatistics, Yale School of Public Health, 60 College Street, New Haven, Connecticut, 06520, USA.
Harvey A RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, 60 College Street, New Haven, CT, 06520-8034, USA. harvey.risch@yale.edu.ORCID http://orcid.org/0000-0001-5337-3941
Yale University · USMemorial Sloan Kettering Cancer Center · USJohns Hopkins University · USNational Institutes of Health · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Pancreatic Cancer Genetic Epidemiology Consortium (PACGENE)R01CA097075 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2002 to 2012
$15.8M
Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci (Study)R01CA154823 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, ALISON P · 2011 to 2020
$5.7M
Case-Control Study of Pancreas Cancer Etiologic FactorsR01CA098870 · NCI · YALE UNIVERSITY · PI RISCH, HARVEY A · 2003 to 2008
$3.5M
Multi-Ancestry Mapping of Pancreatic Cancer Susceptibility LociU01CA247283 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, ALISON P · 2020 to 2025
$3.5M
YALE BIOMEDICAL SUPERCOMPUTER: NEUROSCIENCES10RR019895 · NCRR · YALE UNIVERSITY · PI WILLIAMS, KENNETH ROBERT · 2004 to 2004
$1.6M
High Performance Computing Instrumentation for Yale University Biomedical HPC CenS10RR029676 · NCRR · YALE UNIVERSITY · PI BJORNSON, ROBERT DEAN · 2011 to 2011
$588k
Genome-wide Case-control Association Study of Pancreatic Cancer in JewsF31CA177153 · NCI · YALE UNIVERSITY · PI STREICHER, SAMANTHA ACSON · 2013 to 2015
Jews are estimated to be at increased risk of pancreatic cancer compared to non-Jews, but their observed 50-80% excess risk is not explained by known non-genetic or genetic risk factors. We conducted a GWAS in a case-control sample of American Jews, largely Ashkenazi, including 406 pancreatic cancer patients and 2332 controls, identified in the dbGaP, PanScan I/II, PanC4 and GERA data sets. We then examined resulting SNPs with P < 10
Indexed as
AllelesCase-Control StudiesChromosomes, Human, Pair 19Genetic Predisposition to DiseaseGenome-Wide Association StudyHumansJewsPancreatic NeoplasmsPolymorphism, Single Nucleotide
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A pooled genome-wide association study identifies pancreatic cancer susceptibility loci on chromosome 19p12 and 19p13.3 in the full-Jewish population. · full record | OpenQuestion